Spine

FDA clears Xtant Medical’s new laminoplasty system; shares up 16% premarket

By: Douglas W. House, SA News Editor

Thinly traded nano cap Xtant Medical Holdings (NYSEMKT:XTNT) is up 16% premarket, albeit on turnover of only 2,200 shares, in response to its announcement that wholly owned subsidiary X-spine Systems has received FDA clearance of its Xspan Laminoplasty Fixation System.

Laminoplasty is a surgical procedure to relieve pressure on the spinal cord due to stenosis (narrowing of the canal). It involves cutting a portion of the vertebrae called the lamina to relieve the compression. The lamina is then restructured by a small plate that allows the spinal canal to increase in size without losing stability or movement in the vertebrae.

READ THE REST HERE

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button